Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies.
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies.
复制标题
为诊断B细胞恶性肿瘤而开发的抗CD20聚合物纳米颗粒的靶向肿瘤成像。
DOI：
10.2147/ijn.s78995
复制
发表时间：
2015
影响因子：
8
通讯作者：
Biffi S
中科院分区：
文献类型：
--
作者：
Capolla S;Garrovo C;Zorzet S;Lorenzon A;Rampazzo E;Spretz R;Pozzato G;Núñez L;Tripodo C;Macor P;Biffi S
与常规治疗方法相比，基于纳米颗粒（NP）的靶向药物递送系统在癌症中的预期是更高的疗效和减少的药物副作用，这是由于特定的细胞水平相互作用。然而，关于靶向纳米颗粒增强肿瘤蓄积的文献报道存在冲突，这对于将其应用转化为癌症成像中的改进的药物递送系统和造影剂至关重要。在这项研究中，我们的特点是生物可降解的纳米粒子与抗CD 20抗体结合，在体内成像和药物输送到肿瘤细胞。在MEC 1细胞和慢性淋巴细胞白血病患者细胞上评估抗CD 20抗体介导的NPs结合特异性。在B细胞恶性肿瘤的局部人/小鼠模型中，通过时域光学成像比较非靶向NP和抗CD 20 NP的全身分布。这些研究提供证据表明，与非靶向NP相比，通过抗CD 20抗体的NP功能化改善了全身施用后的体内肿瘤药代动力学特征，并增加了肿瘤块的体内成像。药物递送和成像探针一起代表了靶向B细胞恶性肿瘤的有前途的治疗诊断工具。
The expectations of nanoparticle (NP)-based targeted drug delivery systems in cancer, when compared with convectional therapeutic methods, are greater efficacy and reduced drug side effects due to specific cellular-level interactions. However, there are conflicting literature reports on enhanced tumor accumulation of targeted NPs, which is essential for translating their applications as improved drug-delivery systems and contrast agents in cancer imaging. In this study, we characterized biodegradable NPs conjugated with an anti-CD20 antibody for in vivo imaging and drug delivery onto tumor cells. NPs’ binding specificity mediated by anti-CD20 antibody was evaluated on MEC1 cells and chronic lymphocytic leukemia patients’ cells. The whole-body distribution of untargeted NPs and anti-CD20 NPs were compared by time-domain optical imaging in a localized human/mouse model of B-cell malignancy. These studies provided evidence that NPs’ functionalization by an anti-CD20 antibody improves tumor pharmacokinetic profiles in vivo after systemic administration and increases in vivo imaging of tumor mass compared to non-targeted NPs. Together, drug delivery and imaging probe represents a promising theranostics tool for targeting B-cell malignancies.